A Registration Study on Depression in Patients With Epilepsy

NCT ID: NCT03247764

Last Updated: 2022-01-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

320 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-02-01

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to register the drug treatment of depression in patients with epilepsy in East China.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As the treatment rate for depression in epilepsy is unclear and the discordant voice of choosing antidepressants for most doctors, this prospective observational cohort study was designed to better understand the current situation of drug treatments in patients with the comorbidity of epilepsy and depression in East China. The secondary outcome was to investigate whether baseline depressive symptoms had an influence on seizure-control in patients with epilepsy at follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients with the comorbidity of epilepsy and depression

the clinical data, psychological assessment, and drug treatments will be investigated in patients with the comorbidity of epilepsy and depression

Intervention Type OTHER

observational study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

observational study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

The inclusion criteria were as follows: (1) age 18-75, no gender limited; (2) diagnosis of epilepsy according to the definition by ILAE in 2014; (3) the score of 17-item Hamilton Depression Rating Scale greater than 7; (4) Obtaining informed consent of participants.

Exclusion Criteria

The exclusion criteria were any of the following: (1) having psychiatric symptoms such as hallucination or delusion; (2) progressive neurological diseases and malignant tumors; (3) severe cognitive dysfunction (the score of MMSE less than 10).
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Zhongshan Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xin Wang, PhD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Department of Neurology, Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Site Status RECRUITING

Anhui Provincial Hospital

Hefei, , China

Site Status RECRUITING

Nanjing Brain Hospital

Nanjing, , China

Site Status RECRUITING

Shanghai General Hospital

Shanghai, , China

Site Status RECRUITING

The Second Affiliated Hospital of Suzhou University

Suzhou, , China

Site Status RECRUITING

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Weifeng Peng, MD

Role: CONTACT

862164041990 ext. 2976

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Zhen Hong, MD

Role: primary

86-021-52889999

Meiping Ding, MD

Role: primary

86-0571-87783777

Ruobin Qian

Role: primary

Xiaoshan Wang

Role: primary

Ming Zhu

Role: primary

Chunfeng Liu

Role: primary

Huiqin Xu

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Regist-EP and DP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment for Post-Stroke Depression
NCT00029172 COMPLETED PHASE4